news
-
2 October 2019Axonics® Announces Exclusive Agreement to Supply Sacral Neuromodulation Systems to Leading Urology Practice Group
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device, today announced that it has entered into an exclusive agreement to supply the Axonics r-SNM® System to Adult Pediatric Urology and Urogynecology (“ADPU”), headquartered in Omaha, Nebraska.
ADPU is a pioneering institution in the SNM treatment of urinary and bowel dysfunction, and its physicians have been successfully implanting SNM devices for more than a decade, purchasing approximately $2.5 million annually. ADPU is the first large group practice in the United States that has agreed to make Axonics the sole supplier of r-SNM® Systems for its patients.
The ADPU practice consists of urologists and urogynecologists in three office locations serving patients in Nebraska, Iowa and South Dakota. The Omaha site includes an accredited outpatient surgery center. In addition to treating urinary and bowel dysfunction, the focus of the practice includes, among other things, treatments for bladder, kidney and prostate cancer, benign prostatic hyperplasia, erectile dysfunction and pelvic organ prolapse.
Rebecca J. McCrery, M.D., board certified in Female Pelvic Medicine and Reconstructive Surgery, said, “We are excited to be the first private group practice in America to work exclusively with Axonics. We believe the advantages of the Axonics System are significant compared to the legacy product. The small size of the implant and long-lived nature of the rechargeable system will mitigate numerous replacement surgeries. The easy-to-use programmer, intuitive accessories and MRI compatibility combine for a superior patient experience. Axonics is clearly committed to this market, and we encourage our fellow implanters to make the switch.”
Related
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of NICE Briefing
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock
Axonics® Receives Technology Innovation Award from Medtech Insight
Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System
Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System
Axonics Announces $40 Million Financing
Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia
Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Announces $20.5 Million Second Closing of its Series C Financing
Axonics Announces $14.5 Million First Close of Series C Financing
Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology
Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling
Axonics Announces First Patients Treated in Sacral Neuromodulation Study
Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology
Axonics Modulation Technologies Announces $38.5 Million Series B Financing